Navigation Links
Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
Date:6/17/2011

ructions, this side effect may be reduced or it may go away over time.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Some medications interact with RISPERDAL®. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid alcohol while taking RISPERDAL®.

Inform your healthcare professional if you are pregnant or if you are planning to get pregnant while taking RISPERDAL®. Do not breast-feed if you are taking RISPERDAL®.

RISPERDAL® may affect your driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional.

RISPERDAL® may affect alertness and motor skills; use caution until the effect of RISPERDAL is known.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and gove
'/>"/>

SOURCE Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
2. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
3. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
5. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
6. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
7. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
8. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
9. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
10. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
11. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... -- Investor-Edge has initiated coverage on the ... ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), ... Pharmaceuticals Inc. (NASDAQ: IDRA ), and Merrimack ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,419.48, up 2.40%, the Dow Jones Industrial ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014   ... a world-renowned leader in the field of infertility, ... approach to embryonic screening. The research abstract, released ... for Reproductive Medicine (ASRM) meeting in ... (CCS) and single gene defect (SGD) pre-implantation genetic ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... 2011  Radient Pharmaceuticals Corporation  (OTCQX:RXPC) (OTCPK:RXPC), developer and ... (IVD) cancer test, today announced it has ... Noteholders (who hold convertible notes and shares of ... Anstalt ("Alpha") and Whalehaven Capital Fund Ltd. ("Whalehaven").  ...
... 29, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI), through ... announces it active participation at " HOW TO BECOME A GLOBAL ... for Chinese Companies Going Global " ... Corporation and Loeb & Loeb LLP, a seminar held in Shanghai, ...
Cached Medicine Technology:Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital 2Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital 3China Health Resource Goes Global 2China Health Resource Goes Global 3
(Date:10/22/2014)... 2014 On October 22, CBS will ... skin diseases both fictional and real. The Charles ... organization committed to advocacy and philanthropy in the battle ... the opportunity to impart truth and clarity about this ... are many misconceptions about Morgellons Disease (MD) ...
(Date:10/22/2014)... Norton HealthDay Reporter , TUESDAY, ... the three Ebola cases in Dallas. But, mental health specialists ... Americans. President Barack Obama on Friday appointed an Ebola ... has infected two Dallas nurses who cared for a Liberian ... Presbyterian Hospital. But the U.S. cases are miniscule in ...
(Date:10/22/2014)... Hay House is pleased to announce the official ... Life (Paperback; $10.82) written by the highly esteemed Tommy Rosen, ... book is meant to help readers of all kinds end ... , Recovery 2.0 is not the average self-help book, or ... guide for what comes next. For many, Alcoholics ...
(Date:10/22/2014)... Plano, Texas (PRWEB) October 22, 2014 ... convenience of completing their continuing education at home ... now have access to 20 brand new, premium ... HomeCEUConnection.com’s robust catalog of over 2,000 hours ... to fully customize their educational experience. With such ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Richard Carlson, ... an industry leader with over 25 years experience. ... leader in the areas related to EDI, B2B Commerce, ... is an Editorial Advisory Board member for Pharmaceutical Commerce ... Blue Fin Group is a management and technology ...
Breaking Medicine News(10 mins):Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... 5-Year Contract Makes AccuVein,s Device Now Available to Veteran ... N.Y., June 29 AccuVein LLC today announced a ... This agreement brings the AccuVein AV300, the world,s first ... military and veteran hospitals. , , The AccuVein ...
... CryoLife, Inc., (NYSE: CRY ) an implantable ... announced that, according to company data, CryoLife,s BioGlue(R) Surgical ... procedures throughout the world since its introduction into the ... in 2001. BioGlue is a leading surgical adhesive ...
... step closer to preventing kidney stones, osteoporosis , MONDAY, ... contributes to both kidney stones and osteoporosis has been ... promising target for new drugs to better regulate calcium ... gene encoding claudin 14 (CLDN14), a protein expressed in ...
... risky behavior and pessimistic outlook surprises experts, , MONDAY, ... risky behavior reflects a youthful sense of immortality, a ... teens believe they will die before age 35 -- ... research has shown that typically teenagers are no worse ...
... Bayer/Onyx and Boehringer Ingelheim, and Increased Use of Existing ... According to a New Report from Decision Resources , ... one of the world,s leading research and advisory firms ... of targeted agents as well as increased use of ...
... , - 51 Elsevier Journals Receive ... Elsevier, the leading publisher of scientific, technical and ... impact factor performance in 2008. Elsevier overall saw 75% of ... to the 2008,Journal Citation Report(R) published by ThomsonReuters, Elsevier journals,took ...
Cached Medicine News:Health News:AccuVein AV300, First Portable Vein Illumination Device, Now Available on GSA Schedule 2Health News:AccuVein AV300, First Portable Vein Illumination Device, Now Available on GSA Schedule 3Health News:BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide, Company Data Indicates 2Health News:BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide, Company Data Indicates 3Health News:BioGlue(R) Surgical Adhesive Hits 500,000 Procedure Milestone Worldwide, Company Data Indicates 4Health News:Discovery Points to Regulation of Calcium Metabolism 2Health News:15 Percent of U.S. Teens Think They'll Die Young 2Health News:15 Percent of U.S. Teens Think They'll Die Young 3Health News:Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018 2Health News:Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018 3Health News:Elsevier Announces 2008 Journal Impact Factor Highlights 2Health News:Elsevier Announces 2008 Journal Impact Factor Highlights 3
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
Medicine Products: